Given the clinical utility of splice-targeted morpholinos as in Duchenne Muscular Dystrophy (Wood, 2010), we suggest that the morpholino strategy, potentially, could be applied in case of carriers of two APOL1 risk variants to reduce the luminal ER translocation and signal peptide cleavage, thereby leading to a decrease in the extent of cell injury induced by APOL1 risk alleles. The gene discussed is APOL1; the disease is Duchenne muscular dystrophy.